BIOGEN INC. (BIIB)

Insider Trading Filed: 2026-05-05

Key Insights

• Adam Keeney, Head of Corporate Development at Biogen, acquired 939 shares through restricted stock unit (RSU) vesting on May 1, 2026, with a grant date of May 1, 2023, vesting in three equal annual installments.
• Keeney simultaneously sold 455 shares at $187.06 per share, generating approximately $85,000 in proceeds, likely to cover tax obligations from the RSU vesting.
• Following these transactions, Keeney maintains direct beneficial ownership of 6,365 common shares, indicating continued confidence in the company despite partial share disposal.
• The RSU vesting structure and modest insider selling pattern suggests routine equity compensation execution rather than a significant bullish or bearish signal about company prospects.

Sentiment: Neutral Significance: 2/10

View Original Filing →

Quarterly Report Filed: 2026-04-29

Key Insights

• The filing reveals Biogen's Q1 2026 performance with detailed segment reporting across multiple therapeutic programs including MS products (TECFIDERA, VUMERITY, Fumerate, AVONEX, PLEGRIDY), neurology (SPINRAZA, FAMPYRA), and anti-CD20 therapeutics, indicating a diversified revenue base across multiple disease areas.
• The company shows active management of its portfolio through recent acquisitions (Apellis Pharmaceuticals in March 2026 and Alcyone Therapeutics in November 2025), suggesting strategic expansion into new therapeutic areas and continued investment in pipeline growth.
• Evidence of ongoing cost optimization efforts through 2023 workforce reduction initiatives that continue into Q1 2026, indicating management's focus on operational efficiency and margin improvement during this period.
• The filing includes detailed geographic revenue breakdowns for key products comparing Q1 2026 to Q1 2025, demonstrating Biogen's ability to track performance across US and non-US markets separately for major therapeutic franchises.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Current Report Filed: 2026-04-29

Key Insights

• Biogen announced Q1 2026 financial results on April 29, 2026, representing routine quarterly earnings disclosure with the press release furnished as Exhibit 99.1 for investor review.
• The filing is a standard 8-K submission for earnings results and does not indicate any material agreements, leadership changes, or significant corporate events that would materially impact the company.
• The press release was furnished but not filed under SEC regulations, meaning it is not subject to Section 18 liability and was not incorporated by reference into other securities filings, which is typical for earnings announcements.

Sentiment: Neutral Significance: 2/10

View Original Filing →

Current Report Filed: 2026-04-06

Key Insights

• Biogen expects to incur approximately $34 million in acquired in-process research and development, upfront and milestone expenses in Q1 2026, impacting GAAP and non-GAAP earnings per share by $0.19.
• The company does not provide financial guidance for such expenses due to the uncertainty of future transactions, indicating a lack of visibility into R&D spending.
• The filing includes standard forward-looking statement disclaimers, highlighting the risks and uncertainties that could cause actual results to differ from estimates.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-04-03

Key Insights

• Insider Sean Godbout, the Chief Accounting Officer, exercised 181 restricted stock units and sold 54 shares of Biogen stock on April 1, 2026.
• Godbout's net ownership decreased from 1,395.6667 shares to 1,341.6667 shares as a result of this transaction.
• The restricted stock units vested in three equal yearly installments beginning on the first anniversary of the grant date of April 1, 2025.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-03-31

Key Insights

• Biogen is acquiring Apellis Pharmaceuticals through a tender offer and subsequent merger, indicating Biogen's strategic focus on expanding its product portfolio and pipeline.
• The acquisition will cost Biogen up to $45 per share of Apellis, consisting of $41 per share in cash and up to $4 per share in contingent value rights (CVRs) tied to future milestones.
• The transaction is subject to customary conditions, including regulatory approval and a minimum tender threshold of more than 50% of Apellis' outstanding shares.

Sentiment: Positive Significance: 8/10

View Original Filing →

Current Report Filed: 2026-03-11

Key Insights

• Biogen has announced the departure of its Chief Legal Officer, Susan H. Alexander, effective at the end of May 2026. The company has initiated a search to identify its next Chief Legal Officer.
• The departure of the Chief Legal Officer may indicate changes in the company's leadership and strategy, which could have implications for investors.
• Investors should monitor the company's progress in finding a new Chief Legal Officer and any potential impacts on the company's operations and financial performance.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Current Report Filed: 2026-02-11

Key Insights

• The resignation of Caroline Dorsa, Chair of the Biogen Board of Directors, is not related to any disagreement with the company, indicating a smooth transition in leadership.
• The Board has elected Dr. Maria C. Friere to serve as the new Chair, bringing in new leadership and potentially a fresh perspective.
• The timing of this leadership change, prior to the Annual Meeting, suggests the company is proactively managing the transition and maintaining continuity for investors.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Nicole Murphy, the Head of Pharmaceutical Operations and Technology at Biogen, has exercised 8,725 restricted stock units and sold 3,339 shares on February 6, 2026.
• The transactions indicate that Murphy is partially liquidating her equity holdings in Biogen, which could signal a change in her confidence or outlook on the company's prospects.
• The insider selling activity, combined with the vesting and exercise of stock-based compensation, is worth monitoring as it may provide insights into the company's performance and management's perspective.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• The reporting person, Christopher A. Viehbacher, acquired 9,008 shares of common stock through the vesting of restricted stock units, and subsequently sold 4,356 shares to cover tax withholding obligations.
• Viehbacher also acquired an additional 15,453 shares through the vesting of restricted stock units, and sold 6,624 shares to cover tax withholding.
• After these transactions, Viehbacher's direct beneficial ownership of Biogen's common stock increased from 25,451 shares to 29,924 shares.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Priya Singhal, the Head of Development at Biogen, exercised restricted stock units and sold a portion of the acquired shares, which suggests potential insider confidence in the company's future prospects.
• The timing of Singhal's transactions, occurring in early February 2026, may provide insights into Biogen's near-term outlook and potential business developments.
• The relatively large amount of shares involved in this transaction, totaling over 6,900 shares, indicates a significant change in Singhal's beneficial ownership position in the company.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Robin Kramer, the Chief Financial Officer of Biogen, has acquired 5,003 shares of the company's common stock through the vesting of restricted stock units on February 6, 2026.
• Kramer has also sold 1,543 shares to cover tax withholding obligations, leaving him with a net increase of 3,460 shares in his direct ownership of Biogen stock.
• The insider transactions suggest Kramer's continued confidence in Biogen's prospects, as he retains a significant stake of over 11,400 shares in the company.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Adam Keeney, the Head of Corporate Development at Biogen, exercised 5,080 restricted stock units and sold 1,583 shares to cover tax withholding obligations.
• Keeney's net ownership increased from 4,186 shares to 5,881 shares, indicating he is holding onto a significant portion of his equity compensation.
• The timing and magnitude of these transactions suggest Keeney remains confident in Biogen's long-term prospects and is aligning his personal financial interests with those of the company and its shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Rachid Izzar, the Head of Global Product Strategy at Biogen, has exercised 6,889 stock options and restricted stock units, suggesting confidence in the company's future.
• Izzar has sold 2,038 shares to cover tax withholding obligations, indicating he is retaining a significant portion of the shares received.
• The vesting of the stock options and restricted stock units is staggered over multiple years, providing long-term incentives and alignment with shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Insider Dr. Jane Grogan, Head of Research at Biogen, has exercised restricted stock units (RSUs) to acquire 3,258 shares of Biogen common stock, indicating confidence in the company's future.
• Dr. Grogan has also sold a portion of her shares, likely for tax purposes, retaining a significant stake of 4,058 shares in the company.
• The vesting schedule of the RSUs suggests Biogen is incentivizing its research leadership through long-term equity compensation, aligning their interests with shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• Gregory Ginger, an EVP at Biogen, exercised 7,183 stock options and restricted stock units in a series of transactions on February 6, 2026.
• The total number of Biogen shares beneficially owned by Ginger increased from 19,399.7673 to 23,490.7673 as a result of these transactions.
• Ginger sold a portion of the acquired shares to cover tax withholding obligations, indicating some liquidity needs, but overall maintained a significant equity stake in the company.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• The reporting person, Sean Godbout, is the Chief Accounting Officer of Biogen Inc. and has acquired a significant number of shares through the vesting of restricted stock units.
• Godbout has disposed of a portion of the shares acquired through the vesting, likely for tax purposes, but still maintains a substantial direct ownership position in the company.
• The restricted stock unit grants appear to be on a regular annual schedule, providing Godbout with long-term incentive compensation aligned with shareholder interests.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-10

Key Insights

• The reporting person, Susan H. Alexander, who is the EVP and Chief Legal Officer of Biogen Inc. (BIIB), acquired a total of 9,046 shares of BIIB common stock through the vesting of restricted stock units (RSUs) on 02/06/2026.
• The reporting person disposed of 3,504 shares of BIIB common stock to cover tax withholding obligations related to the vesting of the RSUs, leaving her with a total of 41,807 direct shares and 20,082 indirect shares held in a trust.
• The insider transactions suggest the reporting person's continued commitment to and confidence in Biogen's long-term growth and performance, as evidenced by the vesting and retention of a significant portion of the awarded RSUs.

Sentiment: Positive Significance: 6/10

View Original Filing →

Annual Report Filed: 2026-02-06

Key Insights

• The company reported strong revenue growth across its key product segments, including its anti-CD20 therapeutic programs and Alzheimer's collaboration.
• Biogen made strategic acquisitions, such as Reata Pharmaceuticals and HiBio, which could expand its pipeline and drive future growth.
• The company's operating expenses, including selling, general and administrative expenses as well as amortization and impairment of acquired intangible assets, have increased, which could impact profitability.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-06

Key Insights

• Biogen reported its Q4 2025 and full-year 2025 financial results, indicating potential impact on the company's future performance.
• The press release provides details on Biogen's financial condition and results of operations for the reporting period, which could be of interest to investors.
• Investors should review the financial data and disclosures in the 8-K filing to assess Biogen's current state and outlook.

Sentiment: Neutral Significance: 5/10

View Original Filing →